NFSG
VERV

Newbridge Financial Services Group’s Verve Therapeutics VERV Stock Holding History

Newbridge Financial Services Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,340
Closed -$42.7K – 1362
2025
Q1 		$42.7K Buy
9,340
+7,688
+465% +$51.5K 0.01% 399
2024
Q4 		$9.32K Buy
1,652
+1,400
+556% +$7.9K ﹤0.01% 751
2024
Q3 		$1.22K Sell
252
-310
-55% -$1.8K ﹤0.01% 587
2024
Q2 		$2.74K Sell
562
-100
-15% -$629 ﹤0.01% 921
2024
Q1 		$8.79K Sell
662
-1,520
-70% -$20.2K ﹤0.01% 802
2023
Q4 		$30.4K Buy
+2,182
New +$27K 0.01% 509

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Newbridge Financial Services Group's VERV Position: Q2 2025 in Review

Newbridge Financial Services Group sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 9,340 shares — an estimated $42.7K sold.

Newbridge Financial Services Group first reported a position in VERV in Q4 2023 and held it in 6 quarters. The position peaked at $42.7K in Q1 2025. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Newbridge Financial Services Group reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Newbridge Financial Services Group sold 9,340 Verve Therapeutics shares in Q2 2025, an estimated $42.7K.
  • Newbridge Financial Services Group first reported a position in Verve Therapeutics in Q4 2023 and held it in 6 quarters.
  • Newbridge Financial Services Group's Verve Therapeutics position peaked at $42.7K in Q1 2025.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Newbridge Financial Services Group's 13F filing for Q2 2025, filed 19 Aug 2025.